Starling Oncology, Inc.

US$3.62As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:STLNHealthcare
Country USA
PE (Fwd) •••
TSR 6Y CAGR (14.84%)
Div yield —
ROE —
Medical Care Facilities
Beta (5Y) 0.41
PE TTM —
TSR TTM (18.83%)
Mkt cap US$369.2M
ROIC (28.52%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$4.59
26.72%
(77.79%)
Hold 4|8|3|3|0
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.04
0.04
0.04
0.05
18.82%
25.16%
36.64%
42.71%
Revenue$M
39.04
41.23
41.14
41.77
(5.62%)
1.62%
2.43%
6.74%
Peers (US$369.2M)
Cap (US$)
PE
966.9M
—
496.6M
—
299.6M
8.518x
366.6M
66.45x
Capital
TTM
5Y
10Y
Leveragex
0.705
(0.305)
(0.283)
EBIT/Intx
0.378
0.272
0.253
Own earn%
19.08
50.73
62.92
Sh yield%
33.32
32.77
30.66
Owners
Insiders/Inst%
0.67
75.27
Short interest%
4.12
SBC / revenue%
0.34
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
22
Op margin range%
9–14
$1 testx
—
Incr. ROIC%
44